Back to Search
JEFFREY KOZLOWSKI, MD
MD
Nephrology Physician
NPI: 1558352369IndividualAccepts Medicare
Specialties, Licenses & Credentials
Nephrology PhysicianPrimary
Internal Medicine — Nephrology
Code: 207RN0300X
25MA04372700(NJ)
Education
OTHER
Class of 1978
Research & Publications (20)
Substituted 2-(R)-methyl piperazines as muscarinic M(2) selective ligands.
PMID 11859004·Bioorg Med Chem Lett·2002
7-preclinical
Diphenyl sulfoxides as selective antagonists of the muscarinic M2 receptor.
PMID 11055332·Bioorg Med Chem Lett·2000
7-preclinical
[18F]fluorodeoxyglucose positron emission tomography for lung antiinflammatory response evaluation.
PMID 19574441·Am J Respir Crit Care Med·2009
2-rct
Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
PMID 19447876·Clin Cancer Res·2009
8-other
Novel CXCR3 antagonists with a piperazinyl-piperidine core.
PMID 19647429·Bioorg Med Chem Lett·2009
8-other
17Beta-estradiol at low concentrations acts through distinct pathways in normal versus benign prostatic hyperplasia-derived prostate stromal cells.
PMID 19608654·Endocrinology·2009
8-other
Intra-operative pubic arch interference during prostate seed brachytherapy in patients with CT-based pubic arch interference of < or =1cm.
PMID 19272664·Radiother Oncol·2009
8-other
Discovery of novel spirocyclopropyl hydroxamate and carboxylate compounds as TACE inhibitors.
PMID 19054672·Bioorg Med Chem Lett·2009
8-other
Suppressive roles of calreticulin in prostate cancer growth and metastasis.
PMID 19608864·Am J Pathol·2009
7-preclinical
Labelling and biological evaluation of [(11)C]methoxy-Sch225336: a radioligand for the cannabinoid-type 2 receptor.
PMID 18848664·Nucl Med Biol·2008
7-preclinical
Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.
PMID 18835710·Bioorg Med Chem Lett·2008
7-preclinical
Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists.
PMID 17906679·Br J Pharmacol·2008
6-review
Cannabinoid CB(2)-selective inverse agonist protects against antigen-induced bone loss.
PMID 18075852·Immunopharmacol Immunotoxicol·2007
7-preclinical
A non-invasive method for ending thumb- and fingersucking habits.
PMID 18175885·J Clin Orthod·2007
8-other
Optimization of triaryl bis-sulfones as cannabinoid-2 receptor ligands.
PMID 17466519·Bioorg Med Chem Lett·2007
7-preclinical
Sch35966 is a potent, selective agonist at the peripheral cannabinoid receptor (CB2) in rodents and primates.
PMID 17603556·Br J Pharmacol·2007
4-observational
Characterization of peripheral human cannabinoid receptor (hCB2) expression and pharmacology using a novel radioligand, [35S]Sch225336.
PMID 16754676·J Biol Chem·2006
7-preclinical
Hydrolytic stability of terephthaloyl chloride and isophthaloyl chloride.
PMID 17120561·Environ Sci Technol·2006
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 44 GODWIN AVE
MIDLAND PARK, NJ 07432 - Phone
- (201) 447-0013
Quick Facts
- NPI
- 1558352369
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 48
- Publications
- 20
Are you this provider?
Claim Your Profile